Literature DB >> 12486178

Rostral ventromedial medulla neurons that project to the spinal cord express multiple opioid receptor phenotypes.

Silvia Marinelli1, Christopher W Vaughan, Stephen A Schnell, Martin W Wessendorf, MacDonald J Christie.   

Abstract

The rostral ventromedial medulla (RVM) forms part of a descending pathway that modulates nociceptive neurotransmission at the level of the spinal cord dorsal horn. However, the involvement of descending RVM systems in opioid analgesia are a matter of some debate. In the present study, patch-clamp recordings of RVM neurons were made from rats that had received retrograde tracer injections into the spinal cord. More than 90% of identified spinally projecting RVM neurons responded to opioid agonists. Of these neurons, 53% responded only to the mu-opioid agonist D-Ala2, N-Me-Phe4, Gly-ol5 enkephalin, 14% responded only to the kappa-opioid agonist U-69593, and another group responded to both mu and kappa opioids (23%). In unidentified RVM neurons, a larger proportion of neurons responded only to mu opioids (75%), with smaller proportions of kappa- (4%) and mu/kappa-opioid (13%) responders. These RVM slices were then immunostained for tryptophan hydroxylase (TPH), a marker of serotonergic neurons. Forty-percent of spinally projecting neurons and 11% of unidentified neurons were TPH positive. Of the TPH-positive spinally projecting neurons, there were similar proportions of mu- (33%), kappa- (25%), and mu/kappa-opioid (33%) responders. Most of the TPH-negative spinally projecting neurons were mu-opioid responders (67%). These findings indicate that functional opioid receptor subtypes exist on spinally projecting serotonergic and nonserotonergic RVM neurons. The proportions of mu- and kappa-opioid receptors expressed differ between serotonergic and nonserotonergic neurons and between retrogradely labeled and unlabeled RVM neurons. We conclude that important roles exist for both serotonergic and nonserotonergic RVM neurons in the mediation of opioid effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12486178      PMCID: PMC6758433     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  30 in total

1.  The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control.

Authors:  María Rodríguez-Muñoz; Pilar Sánchez-Blázquez; Ana Vicente-Sánchez; Esther Berrocoso; Javier Garzón
Journal:  Neuropsychopharmacology       Date:  2011-08-03       Impact factor: 7.853

Review 2.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

3.  Influence of intramuscular heat stimulation on modulation of nociception: complex role of central opioid receptors in descending facilitation and inhibition.

Authors:  Hao-Jun You; Jing Lei; Gang Ye; Xiao-Li Fan; Qiang Li
Journal:  J Physiol       Date:  2014-07-18       Impact factor: 5.182

Review 4.  Endogenous opioid peptides in the descending pain modulatory circuit.

Authors:  Elena E Bagley; Susan L Ingram
Journal:  Neuropharmacology       Date:  2020-05-15       Impact factor: 5.250

5.  Visceral analgesic effect of 5-HT(4) receptor agonist in rats involves the rostroventral medulla (RVM).

Authors:  Jyoti N Sengupta; Aaron Mickle; Pradeep Kannampalli; Russell Spruell; John McRorie; Reza Shaker; Adrian Miranda
Journal:  Neuropharmacology       Date:  2013-12-12       Impact factor: 5.250

6.  Neuropathic pain is maintained by brainstem neurons co-expressing opioid and cholecystokinin receptors.

Authors:  Wenjun Zhang; Shannon Gardell; Dongqin Zhang; Jennifer Y Xie; Richard S Agnes; Hamid Badghisi; Victor J Hruby; Naomi Rance; Michael H Ossipov; Todd W Vanderah; Frank Porreca; Josephine Lai
Journal:  Brain       Date:  2008-12-02       Impact factor: 13.501

7.  Descending serotonergic facilitation and the antinociceptive effects of pregabalin in a rat model of osteoarthritic pain.

Authors:  Wahida Rahman; Claudia S Bauer; Kirsty Bannister; Jean-Laurent Vonsy; Annette C Dolphin; Anthony H Dickenson
Journal:  Mol Pain       Date:  2009-08-07       Impact factor: 3.395

8.  Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling.

Authors:  Pilar Sánchez-Blázquez; María Rodríguez-Muñoz; Javier Garzón
Journal:  PLoS One       Date:  2010-06-23       Impact factor: 3.240

Review 9.  Preclinical and early clinical investigations related to monoaminergic pain modulation.

Authors:  Kirsty Bannister; Lucy A Bee; Anthony H Dickenson
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  Gz mediates the long-lasting desensitization of brain CB1 receptors and is essential for cross-tolerance with morphine.

Authors:  Javier Garzón; Elena de la Torre-Madrid; María Rodríguez-Muñoz; Ana Vicente-Sánchez; Pilar Sánchez-Blázquez
Journal:  Mol Pain       Date:  2009-03-10       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.